A relatively small revenue miss in 2024. 
It occurred in the diabetes consumer segment.  ( -$400 M, about 3% ).  I like to  think that it's due to less use of insulin, and, less need for glucose supplements. Increasing use of wearable continuous blood monitors might be having an effect.  More useful information may help reduce guessing about dosing.  And hopefully, less need to make a correction using tablets, or especially, glucagon.  I'm just s...